Table 2. Summary of NS3 protease region resistance-associated variants by genotype.
| Residue | V36 | Q41 | F43 | T54 | V55 | Q80 | R109 | I132 | R155 | A156 | D168 | V170 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genotype | ||||||||||||
| 1a (n = 28) | 36A (1) | 170I (28) | ||||||||||
| 1b (n = 165) | 41H (1) | 54S (4) |
80R(1) 80L (1) 80E (3) |
132V (79)+ 132L (2) |
168E (1) | 170I (75) | ||||||
| 2a (n = 23) | 36L (23) | 80G (23) | 132L (23) | 170I (23) | ||||||||
| 3a (n = 125) | 36L (125) | 80R (0.5)* | 132L (125) | 156G (1) | 168Q (125) | 170I (120) | ||||||
| 3b (n = 112) | 36L (112) | 54S (2) | 132L (112) | 168Q (112) | 170I (112) | |||||||
| 6a (n = 303) | 36I (1) |
80R (1) 80K (298) |
132V (3) | 168E (4) | 170I (303) | |||||||
| 6n (n = 19) | ||||||||||||
| 6u (n = 1) | 132L (1) | |||||||||||
| 6v (n = 2) | 132L (2) |
*Nucleic acid ambiguity resulting in two possible amino acid conversions, one WT and one mutated, thus characterized as 0.5
+Considered significant RAV in genotype 1a replicon only; wild-type in genotype 1b replicon
Variants in bold lettering have been shown to have resistance to NS3 protease inhibitors in vitro and in vivo; only these variants were included in calculation of RAV prevalence for each genotype
Variants without bold lettering are present at residues implicated in resistance, but amino acid change not known to confer resistance